FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Claus Roehrborn

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Prostate

Physiology

Co-author Network

Publications

TOP 3
Mostafa M Elhilali; Rosemina Merchant; Peter Pommerville; Claus G Roehrborn; Richard C Yocum; Samuel R Denmeade
Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
Raymond C Rosen; Fritz H Schröder; Flora S Siami; Frederick C W Wu; Hermann M Behre; Joseph D Finn; Julia F Martha; Claus G Roehrborn; Andre B Araujo
Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
Michael J Barry; Alan Cantor; Claus G Roehrborn
Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Claus Roehrborn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mostafa M Elhilali; Rosemina Merchant; Peter Pommerville; Claus G Roehrborn; Richard C Yocum; Samuel R Denmeade
Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
The Journal of urology 2013;189(4):1421-6.
2013: Raymond C Rosen; Fritz H Schröder; Flora S Siami; Frederick C W Wu; Hermann M Behre; Joseph D Finn; Julia F Martha; Claus G Roehrborn; Andre B Araujo
Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
The aging male : the official journal of the International Society for the Study of the Aging Male 2013;16(1):1-7.
2013: Michael J Barry; Alan Cantor; Claus G Roehrborn
Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms.
The Journal of urology 2013;189(3):987-92.
2013: Mehrad Adibi; Deepa Bhat; Brad Hornberger; Ganesh Raj; Claus G Roehrborn; Yair Lotan
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis.
The Journal of urology 2013;189(2):535-40.
2012: Byung-Ha Chung; Seung Hwan Lee; Kim Major-Walker; Francesco Montorsi; Claus G Roehrborn; Paul F Siami; Timothy H Wilson
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
International journal of urology : official journal of the Japanese Urological Association 2012;19(11):1031-5.
2012: Aditya Bagrodia; Karen Delafuente; Varun Rachakonda; Claus G Roehrborn; Joseph Scales; Suzette Toombs; Owen Yeh; Yair Lotan
Surgeon fatigue: impact of case order on perioperative parameters and patient outcomes.
The Journal of urology 2012;188(4):1291-6.
2012: Varant Kupelian; Claus G Roehrborn; Raymond C Rosen; Pradeep Tyagi; Michael B Chancellor; John B McKinlay
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey.
BJU international 2012;110(3):401-7.
2012: Thomas F Chromecki; Harun Fajkovic; Pierre I Karakiewicz; Karl Pummer; Claus G Roehrborn; Douglas S Scherr; Raheela Ashfaq; Eugene K Cha; Maxine Sun; Ashutosh K Tewari; Shahrokh F Shariat
Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
BJU international 2012;110(1):63-8.
2012: Steven A Kaplan; Claus G Roehrborn; Franklin Sun; Jason Gong; Zhonghong Guan
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
BJU international 2012;109(12):1831-40.
2012: Claus G Roehrborn; Timothy H Wilson; Libby K Black
Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.
The Journal of urology 2012;187(5):1732-8.
2012: Mauro Gacci; Steven A Kaplan; Marco Carini; Giovanni Corona; Kevin T McVary; Vincenzo Mirone; Claus G Roehrborn; Matteo Salvi; Sergio Serni; Linda Vignozzi; Mario Maggi
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
European urology 2012;61(5):994-1003.
2012: Russell Blair Egerdie; Anne L Esler; Martin Sanchez Garza; Claus G Roehrborn; Stephen Auerbach; Pierre Costa; David G Wong; Roberta J Secrest
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
The journal of sexual medicine 2012;9(1):271-81.
2011: Shahrokh F Shariat; Christopher E Barbieri; Thomas F Chromecki; Zoran Culig; Julia Hoefer; Pierre I Karakiewicz; Francesco Montorsi; Claus G Roehrborn; Douglas S Scherr; Ilaria T Cavarretta
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.
The Journal of urology 2011;186(5):2107-14.
2011: Mauro Gacci; Francois Giuliano; Dimitris Hatzichristou; Steven A Kaplan; Mario Maggi; Kevin T McVary; Vincenzo Mirone; Hartmut Porst; Ian Eardley; Claus G Roehrborn
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
European urology 2011;60(4):809-25.
2011: Michael J Barry; Joseph M Betz; Alan Cantor; E David Crawford; Harris E Foster; Steven A Kaplan; Karl J Kreder; John W Kusek; Jeannette Y Lee; Andrew McCullough; Kevin T McVary; Sreelatha Meleth; Catherine M Meyers; Michael J Naslund; J Curtis Nickel; Claus G Roehrborn; O Dale Williams; Gerald L Andriole; Andrew L Avins
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
JAMA : the journal of the American Medical Association 2011;306(12):1344-51.
2011: Claus G Roehrborn; Libby K Black
The economic burden of prostate cancer.
BJU international 2011;108(6):806-13.
2011: E David Crawford; Alexa Hughes; Al Baha Barqawi; Colin I O'Donnell; Michael O'Leary; Claus G Roehrborn; Kathryn F Sullivan; Paul Maroni
Validation of the modified American Urological Association symptom score.
The Journal of urology 2011;186(3):945-8.
2011: E David Crawford; Robert F Donnell; Kathryn Hirst; Steven A Kaplan; John W Kusek; Kevin T McVary; Lance A Mynderse; Claus G Roehrborn; Christopher P Smith; Reginald Bruskewitz
Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
The Journal of urology 2011;186(3):965-70.
2011: John T Wei; Wendy J Carman; Martin M Miner; David J Pasta; Claus G Roehrborn; Raymond C Rosen; Allen D Seftel; William D Steers
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
The Journal of urology 2011;186(3):971-6.
2011: Al Baha Barqawi; E David Crawford; Alexa Hughes; Michael O'Leary; Claus G Roehrborn; Nelson Stone; Kathryn F Sullivan; Colin I O'Donnell
Methods of developing UWIN, the modified American Urological Association symptom score.
The Journal of urology 2011;186(3):940-4.
2011: Claus G Roehrborn; Timothy H Wilson; Gerald L Andriole; Libby Black; R Paul Gagnier; J Curtis Nickel; Roger S Rittmaster
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Urology 2011;78(3):641-6.
2011: Henry H Woo; Reginald C Bruskewitz; Peter T Chin; Harcharan S Gill; Thomas A McNicholas; Mark K Plante; Claus G Roehrborn
Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
BJU international 2011;108(1):82-8.
2011: Claus G Roehrborn; Steven A Kaplan; H Lepor; W Volinn
Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.
Prostate cancer and prostatic diseases 2011;14(2):143-8.
2011: Christian Bolenz; Amit Gupta; Claus G Roehrborn; Yair Lotan
Predictors of costs for robotic-assisted laparoscopic radical prostatectomy.
Urologic oncology 2011;29(3):325-9.
2011: Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Update on AUA guideline on the management of benign prostatic hyperplasia.
The Journal of urology 2011;185(5):1793-803.
2011: Lance A Mynderse; Claus G Roehrborn; Alan W Partin; Glenn M Preminger; Eric P Coté
Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia.
The Journal of urology 2011;185(5):1804-10.
2011: Stavros Gravas; Alexander Bachmann; Oliver Reich; Claus G Roehrborn; Peter J Gilling; Jean De La Rosette
Critical review of lasers in benign prostatic hyperplasia (BPH).
BJU international 2011;107(7):1030-43.
2011: Steven A Kaplan; Claus G Roehrborn; P Abrams; C R Chapple; Tamara Bavendam; Zhonghong Guan
Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.
International journal of clinical practice 2011;65(4):487-507.
2011: Claus G Roehrborn; Jack Barkin; Paul Siami; Andrea Tubaro; Timothy H Wilson; Betsy B Morrill; R Paul Gagnier
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
BJU international 2011;107(6):946-54.
2011: Karl-Erik Andersson; william chesney de groat; Kevin T McVary; Tom F Lue; Mario Maggi; Claus G Roehrborn; Jean-Jacques Wyndaele; Thomas Melby; Lars Viktrup
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Neurourology and urodynamics 2011;30(3):292-301.
2011: L Erickstad; G Reed; D Bhat; Claus G Roehrborn; Yair Lotan
Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution.
Prostate cancer and prostatic diseases 2011;14(1):85-9.
2011: Claus G Roehrborn; Gerald L Andriole; Timothy H Wilson; Ramiro Castro; Roger S Rittmaster
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
European urology 2011;59(2):244-9.
2011: Michael K Brawer; Michael B Chancellor; Stacy Loeb; J Curtis Nickel; Jayabalan Nirmal; Alan W Partin; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn
Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.
Reviews in urology 2011;13(3):151-72.
2011: Claus G Roehrborn
Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
The Medical clinics of North America 2011;95(1):87-100.
2010: Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn; Yair Lotan
The influence of body mass index on the cost of radical prostatectomy for prostate cancer.
BJU international 2010;106(8):1188-93.
2010: Gregory A Broderick; Gerald B Brock; Claus G Roehrborn; Steven D Watts; Albert Elion-Mboussa; Lars Viktrup
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Urology 2010;75(6):1452-8.
2010: Stephen Kraus; Roger Dmochowski; Michael E Albo; Lei Xu; Suzanne R Klise; Claus G Roehrborn
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction.
Neurourology and urodynamics 2010;29(5):741-7.
2010: Yair Lotan; Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn
The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons.
BJU international 2010;105(11):1531-5.
2010: Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn; Yair Lotan
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
European urology 2010;57(3):453-8.
2010: Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Rafael Martínez Montelongo; Albert Elion-Mboussa; Lars Viktrup
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
BJU international 2010;105(4):502-7.
2010: J Curtis Nickel; Akira Furuta; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; Ellen Shapiro; Michael K Brawer
Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA.
Reviews in urology 2010;12(2-3):e134-46.
2010: Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Kim Major-Walker; Indrani Nandy; Betsy B Morrill; R Paul Gagnier; Francesco Montorsi
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
European urology 2010;57(1):123-31.
2009: Alexander Roosen; Christopher R Chapple; Roger R Dmochowski; Clare J Fowler; Christian Gratzke; Claus G Roehrborn; Christian G Stief; Karl-Erik Andersson
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature.
European urology 2009;56(5):810-9.
2009: Elisa Martín-Merino; Luis Alberto García-Rodríguez; Elvira Luján Massó-González; Claus G Roehrborn
Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?
The Journal of urology 2009;182(4):1442-8.
2009: Brian T Helfand; Anne K Mongiu; Claus G Roehrborn; Robert F Donnell; Reginald Bruskewitz; Steven A Kaplan; John W Kusek; Laura Coombs; Kevin T McVary
Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial.
The Journal of urology 2009;181(6):2674-9.
2009: Robert S Svatek; Claudio Jeldres; Pierre I Karakiewicz; Nazareno Suardi; Jochen Walz; Claus G Roehrborn; Francesco Montorsi; Kevin Slawin; Shahrokh F Shariat
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
The Prostate 2009;69(8):886-94.
2009: Steven A Kaplan; Claus G Roehrborn; Alan G Meehan; Kenneth S Liu; Alexandra D Carides; Bruce S Binkowitz; Norman L Heyden; E Darracott Vaughan
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Urology 2009;73(5):935-9.
2009: Amit Gupta; Yair Lotan; Raheela Ashfaq; Claus G Roehrborn; Ganesh V Raj; Corinne C Aragaki; Francesco Montorsi; Shahrokh F Shariat
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
European urology 2009;55(5):1124-33.
2009: Steven A Kaplan; Claus G Roehrborn; Christopher Chapple; Raymond C Rosen; Debra E Irwin; Zoe Kopp; Lalitha P Aiyer; Patrick Mollon
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms.
BJU international 2009;103 Suppl 3():48-57.
2009: Jack Barkin; Claus G Roehrborn; Paul Siami; Olivier Haillot; Betsy Morrill; Libby Black; Francesco Montorsi
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
BJU international 2009;103(7):919-26.
2009: Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Edgardo Becher; Bernardino Miñana; Vicenzo Mirone; Ramiro Castro; Timothy Wilson; Francesco Montorsi
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
European urology 2009;55(2):461-71.
2009: Claus G Roehrborn; Steven A Kaplan; J Stephen Jones; Joseph T Wang; Tamara Bavendam; Zhonghong Guan
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
European urology 2009;55(2):472-9.
2009: Claus G Roehrborn
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.
Reviews in urology 2009;11(Suppl 1):S1-8.
2009: Michael K Brawer; Stacy Loeb; Alan W Partin; Naoki Yoshimura; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; J Curtis Nickel; B Shuch; F Pouliot; Arie S Belldegrun; Ellen Shapiro
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
Reviews in urology 2009;11(2):82-107.
2009: Claus G Roehrborn; P Albertsen; M E Stokes; L Black; A Benedict
First-year costs of treating prostate cancer: estimates from SEER-Medicare data.
Prostate cancer and prostatic diseases 2009;12(4):355-60.
2008: Shahrokh F Shariat; Pierre I Karakiewicz; Claus G Roehrborn; Michael W Kattan
An updated catalog of prostate cancer predictive tools.
Cancer 2008;113(11):3075-99.
2008: Edouard J Trabulsi; Richard Valicenti; Alexandra L Hanlon; Thomas M Pisansky; Howard M Sandler; Deborah A Kuban; Charles N Catton; Jeff M Michalski; Michael J Zelefsky; Patrick A Kupelian; Daniel W Lin; Mitchell S Anscher; Kevin Slawin; Claus G Roehrborn; Jeffrey D Forman; Stanley L Liauw; Larry L Kestin; Theodore L DeWeese; Peter T Scardino; Andrew J Stephenson; Alan Pollack
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
Urology 2008;72(6):1298-302; discussion 1302-4.
2008: J Curtis Nickel; Claus G Roehrborn; Michael P O'Leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.
European urology 2008;54(6):1379-84.
2008: Amit Gupta; Pierre I Karakiewicz; Claus G Roehrborn; Yair Lotan; Alexandre R Zlotta; Shahrokh F Shariat
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7385-90.
2008: Claus G Roehrborn
Currently available treatment guidelines for men with lower urinary tract symptoms.
BJU international 2008;102 Suppl 2():18-23.
2008: Claus G Roehrborn
Clinical management of lower urinary tract symptoms with combined medical therapy.
BJU international 2008;102 Suppl 2():13-7.
2008: Claus G Roehrborn; Steven A Kaplan
Special Issue: Current practices in the management of benign prostatic hyperplasia. Introduction.
BJU international 2008;102 Suppl 2():1-2.
2008: Claus G Roehrborn; Steven A Kaplan; Stephen Kraus; Joseph T Wang; Tamara Bavendam; Zhonghong Guan
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Urology 2008;72(5):1061-7; discussion 1067.
2008: Steven A Kaplan; Claus G Roehrborn; Michael Chancellor; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
BJU international 2008;102(9):1133-9.
2008: Shahrokh F Shariat; Claus G Roehrborn; Dolores J Lamb; Kevin Slawin
Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236).
Archives of internal medicine 2008;168(18):2046-7.
2008: Claus G Roehrborn; Kevin T McVary; Albert Elion-Mboussa; Lars Viktrup
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
The Journal of urology 2008;180(4):1228-34.
2008: Steven A Kaplan; Claus G Roehrborn; John D McConnell; Alan G Meehan; Shailaja Surynawanshi; Jeannette Y Lee; Jennifer Rotonda; John W Kusek; Leroy M Nyberg
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
The Journal of urology 2008;180(3):1030-2; discussion 1032-3.
2008: Yair Lotan; Aditya Bagrodia; Claus G Roehrborn; Jan Scott
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier?
Urology 2008;72(3):494-7.
2008: Shahrokh F Shariat; Adam Jenkins; Claus G Roehrborn; Jose A Karam; Key H Stage; Pierre I Karakiewicz
Features and outcomes of patients with grade IV renal injury.
BJU international 2008;102(6):728-33; discussion 733.
2008: Christopher Chapple; Alan J Wein; Paul Abrams; Roger R Dmochowski; François Giuliano; Steven A Kaplan; Kevin T McVary; Claus G Roehrborn
Lower urinary tract symptoms revisited: a broader clinical perspective.
European urology 2008;54(3):563-9.
2008: Steven A Kaplan; Alan J Wein; david staskin; Claus G Roehrborn; William D Steers
Urinary retention and post-void residual urine in men: separating truth from tradition.
The Journal of urology 2008;180(1):47-54.
2008: Shahrokh F Shariat; Jose A Karam; Jochen Walz; Claus G Roehrborn; Francesco Montorsi; Vitaly Margulis; Fred Saad; Kevin Slawin; Pierre I Karakiewicz
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3785-91.
2008: Shahrokh F Shariat; Quoc-Dien Trinh; Allen F Morey; Key H Stage; Claus G Roehrborn; Luc Valiquette; Pierre I Karakiewicz
Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma.
The Journal of trauma 2008;64(6):1451-8.
2008: Robert S Svatek; Jose A Karam; Claus G Roehrborn; Pierre I Karakiewicz; Kevin Slawin; Shahrokh F Shariat
Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3362-6.
2008: Michael P O'Leary; John T Wei; Claus G Roehrborn; Martin Miner
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
BJU international 2008;101(12):1531-5.
2008: Andrea Gallina; Felix K-H Chun; Nazareno Suardi; James A Eastham; Paul Perrotte; Markus Graefen; Georg C Hutterer; Hartwig Huland; Eric A Klein; Alwyn M Reuther; Francesco Montorsi; Alberto Briganti; Shahrokh F Shariat; Claus G Roehrborn; Alexandre de la Taille; Laurent Salomon; Pierre I Karakiewicz
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
BJU international 2008;101(12):1513-8.
2008: Raymond C Rosen; Karin S Coyne; David Henry; Carol L Link; Amy Cinar; Lalitha Padmanabhan Aiyer; Patrick Mollon; Steven A Kaplan; Claus G Roehrborn; Christine Thompson
Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies.
BJU international 2008;101(10):1274-8.
2008: Susan A Hall; Amy Cinar; Carol L Link; Zoe S Kopp; Claus G Roehrborn; Steven A Kaplan; Raymond C Rosen
Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey.
BJU international 2008;101(10):1257-66.
2008: Amy Cinar; Susan A Hall; Carol L Link; Steven A Kaplan; Zoe S Kopp; Claus G Roehrborn; Raymond C Rosen
Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey.
BJU international 2008;101(10):1247-56.
2008: Shahrokh F Shariat; Jochen Walz; Claus G Roehrborn; Francesco Montorsi; Claudio Jeldres; Fred Saad; Pierre I Karakiewicz
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
The Journal of urology 2008;179(4):1593-7.
2008: Shahrokh F Shariat; Jochen Walz; Claus G Roehrborn; Alexandre R Zlotta; Paul Perrotte; Nazareno Suardi; Fred Saad; Pierre I Karakiewicz
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1526-31.
2008: Jose A Karam; Robert S Svatek; Pierre I Karakiewicz; Andrea Gallina; Claus G Roehrborn; Kevin Slawin; Shahrokh F Shariat
Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1418-22.
2008: Claus G Roehrborn
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
BJU international 2008;101 Suppl 3():17-21.
2008: J Curtis Nickel; Claus G Roehrborn
Optimizing the management of prostate diseases: prostatitis and benign prostatic hyperplasia. Introduction.
BJU international 2008;101 Suppl 3():1.
2008: Debra Anne Schwinn; Claus G Roehrborn
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
International journal of urology : official journal of the Japanese Urological Association 2008;15(3):193-9.
2008: Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Cancer 2008;112(5):1058-65.
2008: Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Kim Major-Walker; Betsy Morrill; Francesco Montorsi
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
The Journal of urology 2008;179(2):616-21; discussion 621.
2008: Robert S Svatek; Jose A Karam; Pierre I Karakiewicz; Andrea Gallina; Roberto Casella; Claus G Roehrborn; Shahrokh F Shariat
Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.
The Journal of urology 2008;179(2):478-84; discussion 484.
2008: Shahrokh F Shariat; Dolores J Lamb; Claus G Roehrborn; Kevin Slawin
Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis.
Archives of internal medicine 2008;168(2):235-6.
2008: Shahrokh F Shariat; Dolores J Lamb; Radha G Iyengar; Claus G Roehrborn; Kevin Slawin
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):607-11.
2008: Shahrokh F Shariat; Claus G Roehrborn
Using biopsy to detect prostate cancer.
Reviews in urology 2008;10(4):262-80.
2008: Claus G Roehrborn; Raymond C Rosen
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Clinical interventions in aging 2008;3(3):511-24.
2008: J Curtis Nickel; Daniel Shoskes; Claus G Roehrborn; Mark Moyad
Nutraceuticals in Prostate Disease: The Urologist's Role.
Reviews in urology 2008;10(3):192-206.
2008: Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Shing-Hwa Lu; Naoki Yoshimura; Michael B Chancellor; Dean G Assimos
Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
Reviews in urology 2008;10(2):136-56.
2008: Claus G Roehrborn
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations.
Reviews in urology 2008;10(1):14-25.
2008: Shahrokh F Shariat; Robert S Svatek; Wareef Kabbani; Jochen Walz; Yair Lotan; Pierre I Karakiewicz; Claus G Roehrborn
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
BJU international 2008;101(2):232-7.
2007: Theodore M Johnson; Pamela K Burrows; John W Kusek; Leroy M Nyberg; J Lisa Tenover; Herbert Lepor; Claus G Roehrborn
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
The Journal of urology 2007;178(5):2045-50; discussion 2050-1.
2007: Paul Siami; Claus G Roehrborn; Jack Barkin; Ronaldo Damiao; Marek Wyczolkowski; Annette Duggan; Kim Major-Walker; Betsy B Morrill
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Contemporary clinical trials 2007;28(6):770-9.
2007: Andrea Gallina; Claudio Jeldres; Felix K-H Chun; Shahrokh F Shariat; Alberto Briganti; Jochen Walz; Claus G Roehrborn; Fred Saad; Hartwig Huland; Markus Graefen; Francesco Montorsi; Pierre I Karakiewicz
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL.
European urology 2007;52(5):1374-80.
2007: Claus G Roehrborn; James G Nuckolls; John T Wei; William Steers
The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.
BJU international 2007;100(4):813-9.
2007: Shahrokh F Shariat; Sangtae Park; Quoc-Dien Trinh; Claus G Roehrborn; Kevin Slawin; Pierre I Karakiewicz
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
The Journal of urology 2007;178(4 Pt 1):1229-36; discussion 1236-7.
2007: Felix K-H Chun; Alberto Briganti; Andrea Gallina; Georg C Hutterer; Shahrokh F Shariat; Elie Antebie; Jochen Walz; Claus G Roehrborn; Andrea Salonia; Patrizio Rigatti; Fred Saad; Hartwig Huland; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
European urology 2007;52(4):1067-74.
2007: Shahrokh F Shariat; Karim Bensalah; Jose A Karam; Claus G Roehrborn; Andrea Gallina; Yair Lotan; Kevin Slawin; Pierre I Karakiewicz
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5377-84.
2007: Janet van Adelsberg; Peter H Gann; Amy T Ko; Jan-Erik Damber; Christopher Logothetis; Michael Marberger; Bernd J Schmitz-Drager; Andrea Tubaro; Celia J Harms; Claus G Roehrborn
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
Current medical research and opinion 2007;23(9):2063-70.
2007: J Curtis Nickel; Claus G Roehrborn; Michael P O'Leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
The Journal of urology 2007;178(3 Pt 1):896-900; discussion 900-1.
2007: Alberto Briganti; Shahrokh F Shariat; Felix K-H Chun; Georg C Hutterer; Claus G Roehrborn; Andrea Gallina; Patrizio Rigatti; Luc Valiquette; Francesco Montorsi; Pierre I Karakiewicz
Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
BJU international 2007;100(3):528-32.
2007: Shahrokh F Shariat; Jose A Karam; Claus G Roehrborn
Blood biomarkers for prostate cancer detection and prognosis.
Future oncology (London, England) 2007;3(4):449-61.
2007: Bahaa S Malaeb; Hani H Rashid; Yair Lotan; Seyyed M Khoddami; Shahrokh F Shariat; Arthur I Sagalowsky; John D McConnell; Claus G Roehrborn; Kenneth S Koeneman
Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Urologic oncology 2007;25(4):291-7.
2007: Robert Serfling; Michael J Shulman; G L Thompson; Zhiyao Xiao; Elie A Benaim; Claus G Roehrborn; Roger S Rittmaster
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
The Journal of urology 2007;177(6):2352-6.
2007: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin Slawin; Eric A Klein; Mitchell S. Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard Valicenti; Deborah A Kuban; Alan Pollack
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2035-41.
2007: Jose A Karam; Yair Lotan; Claus G Roehrborn; Raheela Ashfaq; Pierre I Karakiewicz; Shahrokh F Shariat
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
The Prostate 2007;67(6):614-22.
2007: Shahrokh F Shariat; Claus G Roehrborn; Pierre I Karakiewicz; Gurleen Dhami; Key H Stage
Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale.
The Journal of trauma 2007;62(4):933-9.
2007: Leonard S Marks; Claus G Roehrborn; Eric Wolford; Timothy H Wilson
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
The Journal of urology 2007;177(4):1408-13.
2007: Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
The Journal of urology 2007;177(4):1401-7.
2007: Jose A Karam; Yair Lotan; Pierre I Karakiewicz; Raheela Ashfaq; Arthur I Sagalowsky; Claus G Roehrborn; Shahrokh F Shariat
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
The lancet oncology 2007;8(2):128-36.
2007: Shahrokh F Shariat; Claus G Roehrborn; John D McConnell; Sangtae Park; Nina Alam; Thomas M Wheeler; Kevin Slawin
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(4):349-55.
2007: Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Michael B Chancellor; Dean G Assimos; Ellen Shapiro; Jacob Rajfer
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.
Reviews in urology 2007;9(3):133-54.
2007: Sangtae Park; Omar Jaffer; Yair Lotan; Hossein Saboorian; Claus G Roehrborn; Jeffrey A Cadeddu
Contemporary laparoscopic and open radical retropubic prostatectomy: pathologic outcomes and Kattan postoperative nomograms are equivalent.
Urology 2007;69(1):118-22.
2007: Anthony V D'Amico; Claus G Roehrborn
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.
The lancet oncology 2007;8(1):21-5.
2006: Amit Gupta; Sachin Gupta; Marian Pavuk; Claus G Roehrborn
Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.
Urology 2006;68(6):1198-205.
2006: Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2006;296(19):2319-28.
2006: Amit Gupta; Norma S Ketchum; Claus G Roehrborn; Arnold Schecter; Corinne C Aragaki; Joel Michalek
Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.
Environmental health perspectives 2006;114(11):1649-54.
2006: Leonard S Marks; Claus G Roehrborn; Gerald L Andriole
Prevention of benign prostatic hyperplasia disease.
The Journal of urology 2006;176(4 Pt 1):1299-306.
2006: Shahrokh F Shariat; Michael Marberger; Yair Lotan; Marta Sanchez-Carbayo; Craig D Zippe; Gerson Lüdecke; Hans Boman; Ihor S Sawczuk; Martin G Friedrich; Roberto Casella; Christine Mian; Sanaa Eissa; Hideyuki Akaza; Vincenzo Serretta; Hartwig Huland; Hans Hedelin; Rupesh Raina; Naoto Miyanaga; Arthur I Sagalowsky; Claus G Roehrborn; Pierre I Karakiewicz
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
The Journal of urology 2006;176(3):919-26; discussion 926.
2006: Leonard S Marks; Gerald L Andriole; John M Fitzpatrick; Claude C Schulman; Claus G Roehrborn
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
The Journal of urology 2006;176(3):868-74.
2006: Steven A Kaplan; Claus G Roehrborn; Roger Dmochowski; Eric S Rovner; Joseph T Wang; Zhonghong Guan
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Urology 2006;68(2):328-32.
2006: Claus G Roehrborn
Saw palmetto for benign prostatic hyperplasia: just how effective is it?
Nature clinical practice. Urology 2006;3(8):420-1.
2006: Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
The cost of prostate cancer chemoprevention: a decision analysis model.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(8):1485-9.
2006: Felix K-H Chun; Alberto Briganti; Shahrokh F Shariat; Markus Graefen; Francesco Montorsi; Andreas Erbersdobler; Thomas Steuber; Andrea Salonia; Eike Currlin; Vincenzo Scattoni; Martin G Friedrich; Thorsten Schlomm; Alexander Haese; Uwe Michl; Renzo Colombo; Hans Heinzer; Luc Valiquette; Patrizio Rigatti; Claus G Roehrborn; Hartwig Huland; Pierre I Karakiewicz
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
BJU international 2006;98(2):329-34.
2006: Amit Gupta; Arnold Schecter; Corinne C Aragaki; Claus G Roehrborn
Dioxin exposure and benign prostatic hyperplasia.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2006;48(7):708-14.
2006: Claus G Roehrborn; Paul Abrams; Eric S Rovner; Steven A Kaplan; Sender Herschorn; Zhonghong Guan
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
BJU international 2006;97(5):1003-6.
2006: Gerald L Andriole; Michael Marberger; Claus G Roehrborn
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
The Journal of urology 2006;175(5):1657-62.
2006: Claus G Roehrborn
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
BJU international 2006;97(4):734-41.
2006: Christopher Chapple; Claus G Roehrborn
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
European urology 2006;49(4):651-8.
2006: E David Crawford; Shandra S Wilson; John D McConnell; Kevin Slawin; Michael C Lieber; Joseph A Smith; Alan G Meehan; Oliver M Bautista; William R Noble; John W Kusek; Leroy M Nyberg; Claus G Roehrborn
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
The Journal of urology 2006;175(4):1422-6; discussion 1426-7.
2006: Claus G Roehrborn
Definition of at-risk patients: baseline variables.
BJU international 2006;97 Suppl 2():7-11; discussion 21-2.
2006: Michael Marberger; Claus G Roehrborn; Leonard S Marks; Timothy Wilson; Roger S Rittmaster
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
The Journal of clinical endocrinology and metabolism 2006;91(4):1323-8.
2006: Claus G Roehrborn; Yair Lotan; Andrea Tubaro; Cosimo de Nunzio
Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
European urology 2006;49(2):396-400.
2006: Shahrokh F Shariat; Khaled F Abdel-Aziz; Claus G Roehrborn; Yair Lotan
Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
European urology 2006;49(2):293-302.
2006: Claus G Roehrborn
Advances in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: highlights from the 21st European association of urology congress, april 5-8, 2006, paris, france.
Reviews in urology 2006;8(4):216-25.
2006: Claus G Roehrborn
Safety and efficacy of the potassium-titanyl-phosphate laser and photoselective vaporization of the prostate for benign prostatic hyperplasia.
Reviews in urology 2006;8 Suppl 3():S16-23.
2006: Claus G Roehrborn; P Ray
Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.
Prostate cancer and prostatic diseases 2006;9(4):432-8.
2006: Kevin Slawin; Michael W Kattan; Claus G Roehrborn; Timothy Wilson
Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.
Urology 2006;67(1):84-8.
2006: Steven A Kaplan; John D McConnell; Claus G Roehrborn; Alan G Meehan; Michael W Lee; William R Noble; John W Kusek; Leroy M Nyberg
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
The Journal of urology 2006;175(1):217-20; discussion 220-1.
2006: Claus G Roehrborn
Drug treatment for LUTS and BPH: new is not always better.
European urology 2006;49(1):5-7.
2006: Claus G Roehrborn
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Prostate cancer and prostatic diseases 2006;9(2):121-5.
2005: Gerald L Andriole; David Bostwick; Francisco Civantos; Jonathan I Epstein; M Scott Lucia; John McConnell; Claus G Roehrborn
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
The Journal of urology 2005;174(6):2098-104.
2005: Shahrokh F Shariat; Raheela Ashfaq; Claus G Roehrborn; Kevin Slawin; Yair Lotan
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
The Journal of urology 2005;174(5):2046-50.
2005: Claus G Roehrborn; Olavi Lukkarinen; Stephen Mark; Paul Siami; Joe Ramsdell; Norman Zinner
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
BJU international 2005;96(4):572-7.
2005: Claus G Roehrborn; Andrzej Prajsner; Roger Kirby; Morton Andersen; Sheila Quinn; Sharon Mallen
A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
European urology 2005;48(3):445-52; discussion 452.
2005: Victor K Lin; Shih-Ya Wang; Nicholas C Boetticher; Dolores V Vazquez; Hossein Saboorian; John D McConnell; Claus G Roehrborn
Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma.
The Prostate 2005;63(3):299-308.
2005: Shahrokh F Shariat; Craig D Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Ihor S Sawczuk; Vincenzo Serretta; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Frank H Wians; Claus G Roehrborn; Yair Lotan; Paul Perrotte; Serge Benayoun; Michael Marberger; Pierre I Karakiewicz
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
The Journal of urology 2005;173(5):1518-25.
2005: Yair Lotan; Jeffrey A Cadeddu; J Jack Lee; Claus G Roehrborn; Scott M Lippman
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1911-20.
2005: Brad J Hornberger; James M Elmore; Claus G Roehrborn
Idiopathic scrotal elephantiasis.
Urology 2005;65(2):389.
2005: Amit Gupta; Corinne Aragaki; Momokazu Gotoh; Naoya Masumori; Shinichi Ohshima; Taiji Tsukamoto; Claus G Roehrborn
Relationship between prostate specific antigen and indexes of prostate volume in Japanese men.
The Journal of urology 2005;173(2):503-6.
2005: Claus G Roehrborn
The development of lonidamine for benign prostatic hyperplasia and other indications.
Reviews in urology 2005;7 Suppl 7():S12-20.
2005: Claus G Roehrborn
Acute urinary retention: risks and management.
Reviews in urology 2005;7 Suppl 4():S31-41.
2005: Claus G Roehrborn
Benign prostatic hyperplasia: an overview.
Reviews in urology 2005;7 Suppl 9():S3-S14.
2005: Claus G Roehrborn
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia.
Reviews in urology 2005;7 Suppl 8():S43-51.
2005: S Alan McNeill; Timothy B Hargreave; Claus G Roehrborn
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Urology 2005;65(1):83-9; discussion 89-90.
2004: Yair Lotan; Jeffrey A Cadeddu; Claus G Roehrborn; Key H Stage
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology.
The Journal of urology 2004;172(5 Pt 1):1958-62.
2004: Gerald L Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger S Rittmaster; Claus G Roehrborn; David Russell; Donald Tindall
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
The Journal of urology 2004;172(4 Pt 1):1399-403.
2004: Frans Debruyne; Jack Barkin; Peter van Erps; Mario Reis; Teuvo L J Tammela; Claus G Roehrborn
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
European urology 2004;46(4):488-94; discussion 495.
2004: Gerald L Andriole; Claus G Roehrborn; C Schulman; Kevin Slawin; Matthew C Somerville; Roger S Rittmaster
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Urology 2004;64(3):537-41; discussion 542-3.
2004: Elie A Benaim; Jose A Karam; M Hossein Soboorian; Claus G Roehrborn; John D McConnell; Victor Lin
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
The Prostate 2004;60(4):310-6.
2004: Kenneth Ogan; Lucas Jacomides; Michael J Shulman; Claus G Roehrborn; Jeffrey A Cadeddu; Margaret S Pearle
Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver.
The Journal of urology 2004;172(2):667-71.
2004: Amit Gupta; Claus G Roehrborn
Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example.
Urology 2004;64(1):106-11.
2004: Seyed M Khoddami; Shahrokh F Shariat; Yair Lotan; Hossein Saboorian; John D McConnell; Arthur I Sagalowsky; Claus G Roehrborn; Kenneth S Koeneman
Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
BJU international 2004;94(1):42-6.
2004: Amit Gupta; Claus G Roehrborn; Corinne Aragaki
Re: complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
The Journal of urology 2004;171(6 Pt 1):2384-5; author reply 2385.
2004: Brian Hill; William Belville; Reginald C Bruskewitz; Muta M Issa; Ramon Perez-Marrero; Claus G Roehrborn; Martha Kennedy Terris; Michael J Naslund
Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.
The Journal of urology 2004;171(6 Pt 1):2336-40.
2004: Yair Lotan; Shahrokh F Shariat; Seyed M Khoddami; Hossein Saboorian; Kenneth S Koeneman; Jeffrey A Cadeddu; Arthur I Sagalowsky; John D McConnell; Claus G Roehrborn
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
The Journal of urology 2004;171(6 Pt 1):2209-14.
2004: Bruce J Trock; Michelle Brotzman; William J Utz; Roland R Ugarte; Steven A Kaplan; Thayne R Larson; Michael L Blute; Claus G Roehrborn; Alan W Partin
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Urology 2004;63(4):716-21.
2004: Claus G Roehrborn; Leonard S Marks; Tom Fenter; Sheldon Freedman; John Tuttle; Marc Gittleman; Betsy Morrill; Eric T Wolford
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Urology 2004;63(4):709-15.
2004: Andrew J Stephenson; Shahrokh F Shariat; Michael J Zelefsky; Michael W Kattan; E. Brian Butler; Bin S Teh; Eric A Klein; Patrick A Kupelian; Claus G Roehrborn; David A Pistenmaa; Heather D Pacholke; Stanley L Liauw; Matthew Katz; Steven A Leibel; Peter T Scardino; Kevin Slawin
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
JAMA : the journal of the American Medical Association 2004;291(11):1325-32.
2004: David G Bostwick; Junqi Qian; Francisco Civantos; Claus G Roehrborn; Rodolfo Montironi
Does finasteride alter the pathology of the prostate and cancer grading?
Clinical prostate cancer 2004;2(4):228-35.
2004: Claus G Roehrborn; Reginald C Bruskewitz; J Curtis Nickel; John D McConnell; Brian Saltzman; Marc Gittelman; Gholem H Malek; James E Gottesman; Shilaja Suryawanshi; Jennifer Drisko; Alan G Meehan; Joanne Waldstreicher
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
The Journal of urology 2004;171(3):1194-8.
2004: Shahrokh F Shariat; Seyed M Khoddami; Hossein Saboorian; Kenneth S Koeneman; Arthur I Sagalowsky; Jeffrey A Cadeddu; John D McConnell; Marisa N Holmes; Claus G Roehrborn
Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.
The Journal of urology 2004;171(3):1122-7.
2004: Claus G Roehrborn; Debra Anne Schwinn
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
The Journal of urology 2004;171(3):1029-35.
2004: Shahrokh F Shariat; Yair Lotan; Hossein Saboorian; Seyed M Khoddami; Claus G Roehrborn; Kevin Slawin; Raheela Ashfaq
Survivin expression is associated with features of biologically aggressive prostate carcinoma.
Cancer 2004;100(4):751-7.
2004: Claus G Roehrborn
The Clinical Benefits of Dutasteride Treatment for LUTS and BPH.
Reviews in urology 2004;6 Suppl 9():S22-30.
2004: Claus G Roehrborn
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.
Reviews in urology 2004;6(3):121-7.
2004: Claus G Roehrborn
39-year-old man with voiding symptoms.
Reviews in urology 2004;6(1):34-8.
2003: John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias C Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin Slawin; Joseph A Smith
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
The New England journal of medicine 2003;349(25):2387-98.
2003: Yair Lotan; Claus G Roehrborn; John D McConnell; Benjamin N Hendin
Factors influencing the outcomes of penile prosthesis surgery at a teaching institution.
Urology 2003;62(5):918-21.
2003: Claus G Roehrborn; Michael Lee; Alan G Meehan; Joanne Waldstreicher
Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Urology 2003;62(5):894-9.
2003: Leonard S Marks; Claus G Roehrborn; Marc Gittelman; Daniel Kim; John Forrest; Sharon Jacobs
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Urology 2003;62(5):888-93.
2003: Claus G Roehrborn
Prevention of prostate cancer with finasteride.
The New England journal of medicine 2003;349(16):1569-72; author reply 1569-72.
2003: Gina A Defreitas; Gary E Lemack; Philippe E Zimmern; Richard B Dewey; Claus G Roehrborn; Padraig E O'Suilleabhain
Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease.
Urology 2003;62(4):651-5.
2003: Claus G Roehrborn; P Van Kerrebroeck; Jørgen Nordling
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
BJU international 2003;92(3):257-61.
2003: Stanley L Liauw; W Scott Webster; David A Pistenmaa; Claus G Roehrborn
Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience.
Urology 2003;61(6):1204-10.
2003: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Margaret S Pearle; Jeffrey A Cadeddu
Laparoscopic nephrectomy is cost effective compared with open nephrectomy in a large county hospital.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2003;7(2):111-5.
2003: Mark Emberton; Gerald L Andriole; Jean J M C H de la Rosette; Bob Djavan; Klaus Hoefner; Remigio Vela-Navarrete; Jørgen Nordling; Claus G Roehrborn; Claude Schulman; Pierre Teillac; Andrea Tubaro; J Curtis Nickel
Benign prostatic hyperplasia: a progressive disease of aging men.
Urology 2003;61(2):267-73.
2003: Jennifer B Sherwood; John D McConnell; Dolores J Vazquez; Victor K Lin; Claus G Roehrborn
Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia.
The Journal of urology 2003;169(2):575-9.
2003: Claus G Roehrborn
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.
Reviews in urology 2003;5 Suppl 5():S12-21.
2003: Claus G Roehrborn
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.
Reviews in urology 2003;5 Suppl 4():S18-27.
2003: Christian Seitz; Mesut Remzi; Bob Djavan; Claus G Roehrborn
Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia: Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002.
Reviews in urology 2003;5(2):90-110.
2003: Roger S Kirby; Claus G Roehrborn; Peter Boyle; Georg Bartsch; Alain Jardin; Margaret M Cary; Michael Sweeney; Eric B Grossman
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
Urology 2003;61(1):119-26.
2003: Yair Lotan; Claus G Roehrborn
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.
Urology 2003;61(1):109-18; discussion 118.
2002: Michael Barry; Claus G Roehrborn; Robyn Webber
Benign prostatic hyperplasia.
Clinical evidence 2002;(8):849-63.
2002: David M Wilhelm; Kenneth Ogan; Claus G Roehrborn; Jeffrey A Cadeddu; Margaret S Pearle
Assessment of basic endoscopic performance using a virtual reality simulator.
Journal of the American College of Surgeons 2002;195(5):675-81.
2002: Claus G Roehrborn; Peter Boyle; J Curtis Nickel; Klaus Hoefner; Gerald L Andriole
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Urology 2002;60(3):434-41.
2002: Elie A Benaim; C M Pace; Claus G Roehrborn
Gleason score predicts androgen independent progression after androgen deprivation therapy.
European urology 2002;42(1):12-7.
2002: Claus G Roehrborn; John D McConnell; Brian Saltzman; Donald Bergner; Todd Gray; Perinchery Narayan; Thomas J Cook; Amy O Johnson-Levonas; Wilson A Quezada; Joanne Waldstreicher
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
European urology 2002;42(1):1-6.
2002: Michael Barry; Claus G Roehrborn
Benign prostatic hyperplasia.
Clinical evidence 2002;(7):775-87.
2002: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Margaret S Pearle; Jeffrey A Cadeddu
Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters.
Urology 2002;59(6):821-5.
2002: Claus G Roehrborn
Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.
Urology 2002;59(6):811-5.
2002: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Jeffrey A Cadeddu; Margaret S Pearle
Management of ureteral calculi: a cost comparison and decision making analysis.
The Journal of urology 2002;167(4):1621-9.
2002: Claus G Roehrborn
Are all alpha-blockers created equal? An update.
Urology 2002;59(2 Suppl 1):3-6.
2002: Claus G Roehrborn
Reducing the risk of benign prostatic hyperplasia progression.
Reviews in urology 2002;4 Suppl 5():S29-38.
2002: Y Lotan; Claus G Roehrborn
Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians.
Prostate cancer and prostatic diseases 2002;5(2):111-4.
2002: Elie A Benaim; Christopher M Pace; Po Mui Lam; Claus G Roehrborn
Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer.
Urology 2002;59(1):73-8.
2002: Yair Lotan; Claus G Roehrborn
Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
The Journal of urology 2002;167(1):75-9.
2001: Claus G Roehrborn
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Urology 2001;58(6 Suppl 1):55-63; discussion 63-4.
2001: Claus G Roehrborn
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Urology 2001;58(6):953-9.
2001: Claus G Roehrborn; G Bartsch; R Kirby; Gerald L Andriole; Peter Boyle; J de la Rosette; P Perrin; E Ramsey; Jørgen Nordling; G De Campos Freire; S Arap
Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview.
Urology 2001;58(5):642-50.
2001: Olivier Traxer; Matthew T Gettman; Cheryl Napper; D J Scott; Daniel B Jones; Claus G Roehrborn; Margaret S Pearle; Jeffrey A Cadeddu
The impact of intense laparoscopic skills training on the operative performance of urology residents.
The Journal of urology 2001;166(5):1658-61.
2001: Claus G Roehrborn; M Malice; Thomas J Cook; CJ Girman
Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.
Urology 2001;58(2):210-6.
2001: P R Showalter; Philippe E Zimmern; Claus G Roehrborn; Gary E Lemack
Standing cystourethrogram: an outcome measure after anti-incontinence procedures and cystocele repair in women.
Urology 2001;58(1):33-7.
2001: SM Sech; J Montoya; CJ Girman; T Rhodes; Claus G Roehrborn
Interexaminer reliability of transrectal ultrasound for estimating prostate volume.
The Journal of urology 2001;166(1):125-9.
2001: Claus G Roehrborn; SM Sech; J Montoya; T Rhodes; CJ Girman
Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination.
Urology 2001;57(6):1087-92.
2001: J B Anderson; Claus G Roehrborn; J A Schalken; M Emberton
The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.
European urology 2001;39(4):390-9.
2001: S Alan McNeill; Timothy B Hargreave; C Geffriaud-Ricouard; J Santoni; Claus G Roehrborn
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Urology 2001;57(3):459-65.
2001: Bob Djavan; Christian Seitz; Claus G Roehrborn; Mesut Remzi; Mitra Fakhari; Matthias Waldert; A Basharkhah; Bernhard Planz; Mike Harik; Michael Marberger
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
Urology 2001;57(1):66-70.
2001: Claus G Roehrborn
Is there a place for combination medical therapy?
Current opinion in urology 2001;11(1):17-25.
2000: Claus G Roehrborn
Acute relief or future prevention: is urology ready for preventive health care?
Urology 2000;56(5 Suppl 1):12-9.
2000: Gary E Lemack; Richard B Dewey; Claus G Roehrborn; Padraig E O'Suilleabhain; Philippe E Zimmern
Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease.
Urology 2000;56(2):250-4.
2000: Claus G Roehrborn; K S Dolte; K S Ross; CJ Girman
Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas.
Urology 2000;56(1):9-18.
2000: Claus G Roehrborn; Reginald C Bruskewitz; G C Nickel; S Glickman; C Cox; R Anderson; S Kandzari; R Herlihy; G Kornitzer; B T Brown; HL Holtgrewe; A Taylor; D Wang; Joanne Waldstreicher
Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
European urology 2000;37(5):528-36.
2000: Bob Djavan; Alan W Partin; M F Hoey; Claus G Roehrborn; C M Dixon; Michael Marberger
Transurethral radiofrequency therapy for benign prostatic hyperplasia using a novel saline-liquid conductor: the virtual electrode.
Urology 2000;55(1):13-6.
2000: Claus G Roehrborn; John McConnell; J Bonilla; S Rosenblatt; Perry B Hudson; Gholem H Malek; P F Schellhammer; Reginald C Bruskewitz; Alvin M Matsumoto; L H Harrison; H A Fuselier; Patrick C Walsh; J Roy; Gerald L Andriole; M Resnick; Joanne Waldstreicher
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
The Journal of urology 2000;163(1):13-20.
1999: J D Wilson; Claus G Roehrborn
Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts.
The Journal of clinical endocrinology and metabolism 1999;84(12):4324-31.
1999: Margaret S Pearle; Claus G Roehrborn; Charles Y C Pak
Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.
Journal of endourology / Endourological Society 1999;13(9):679-85.
1999: Claus G Roehrborn; Peter Boyle; D Bergner; T Gray; Marc Gittelman; T Shown; Arnold Melman; R B Bracken; Ralph W deVere White; A Taylor; D Wang; Joanne Waldstreicher
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Urology 1999;54(4):662-9.
1999: Claus G Roehrborn; F C Burkhard; Reginald C Bruskewitz; Muta M Issa; Ramon Perez-Marrero; Michael J Naslund; BP Shumaker
The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study.
The Journal of urology 1999;162(1):92-7.
1999: MC Hall; R J Fritzsch; Arthur I Sagalowsky; A Ahrens; B Petty; Claus G Roehrborn
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Urology 1999;53(5):898-902; discussion 902-3.
1999: Claus G Roehrborn; Peter Boyle; Lawrence Gould; Joanne Waldstreicher
Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Urology 1999;53(3):581-9.
1999: E Barnboym; A Ahrens; Claus G Roehrborn
Effect of scrambling on the short-term reliability of the American Urological Association Symptom Index.
Urology 1999;53(3):568-73.
1999: Claus G Roehrborn; John D McConnell; Michael Lieber; S Kaplan; Jack Geller; Gholem H Malek; R Castellanos; S Coffield; Brian Saltzman; M Resnick; Thomas J Cook; Joanne Waldstreicher
Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Urology 1999;53(3):473-80.
1999: Bob Djavan; S Shariat; Mitra Fakhari; K Ghawidel; Christian Seitz; Alan W Partin; Claus G Roehrborn; Michael Marberger
Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Urology 1999;53(2):251-9.
1999: Bob Djavan; Claus G Roehrborn; S Shariat; K Ghawidel; Michael Marberger
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
The Journal of urology 1999;161(1):139-43.
1998: Bob Djavan; Mitra Fakhari; Claus G Roehrborn; Michael Marberger
Metabolic consequences of urinary diversion with intestinal segments.
Techniques in urology 1998;4(4):177-81.
1998: P F Fulgham; J S Cochran; J L Denman; B A Feagins; M B Gross; K T Kadesky; M C Kadesky; A R Clark; Claus G Roehrborn
Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting.
The Journal of urology 1998;160(6 Pt 1):2041-6.
1998: MC Hall; S Womack; Arthur I Sagalowsky; T Carmody; M D Erickstad; Claus G Roehrborn
Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients.
Urology 1998;52(4):594-601.
1998: Margaret S Pearle; H L Pierce; G L Miller; JA Summa; J M Mutz; B A Petty; Claus G Roehrborn; John V Kryger; Stephen Y Nakada
Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi.
The Journal of urology 1998;160(4):1260-4.
1998: MC Hall; J S Womack; Claus G Roehrborn; T Carmody; Arthur I Sagalowsky
Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy.
The Journal of urology 1998;160(3 Pt 1):703-6.
1998: Reginald C Bruskewitz; Muta M Issa; Claus G Roehrborn; Michael J Naslund; Ramon Perez-Marrero; BP Shumaker; JE Oesterling
A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia.
The Journal of urology 1998;159(5):1588-93; discussion 1593-4.
1998: Claus G Roehrborn
Meta-analysis of randomized clinical trials of finasteride.
Urology 1998;51(4A Suppl):46-9.
1998: Claus G Roehrborn
Accurate determination of prostate size via digital rectal examination and transrectal ultrasound.
Urology 1998;51(4A Suppl):19-22.
1998: Claus G Roehrborn; Muta M Issa; Reginald C Bruskewitz; Michael J Naslund; JE Oesterling; Ramon Perez-Marrero; BP Shumaker; Perinchery Narayan
Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study.
Urology 1998;51(3):415-21.
1998: S Chassagne; PA Bernier; F Haab; Claus G Roehrborn; Joan S Reisch; Philippe E Zimmern
Proposed cutoff values to define bladder outlet obstruction in women.
Urology 1998;51(3):408-11.
1998: John D McConnell; Reginald C Bruskewitz; Patrick C Walsh; Gerald L Andriole; Michael Lieber; HL Holtgrewe; P Albertsen; Claus G Roehrborn; J Curtis Nickel; D Z Wang; A M Taylor; Joanne Waldstreicher
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
The New England journal of medicine 1998;338(9):557-63.
1998: SM Sech; J D Montoya; PA Bernier; E Barnboym; S Brown; A Gregory; Claus G Roehrborn
The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring.
Urology 1998;51(2):242-50.
1998: Bob Djavan; K Kadesky; B Klopukh; Michael Marberger; Claus G Roehrborn
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.
European urology 1998;33(3):261-70.
1998: Margaret S Pearle; SM Sech; C G Cobb; J R Riley; P J Clark; Glenn M Preminger; G W Drach; Claus G Roehrborn
Safety and efficacy of the Alexandrite laser for the treatment of renal and ureteral calculi.
Urology 1998;51(1):33-8.
1998: Claus G Roehrborn; Glenn M Preminger; P Newhall; John D Denstedt; Hassan Razvi; L J Chin; A Perlmutter; W Barzell; W Whitmore; R Fritzsch; J Sanders; SM Sech; S Womack
Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial.
Urology 1998;51(1):19-28.
1997: Claus G Roehrborn; JE Oesterling; P J Olson; R J Padley
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
Urology 1997;50(4):556-61.
1997: Margaret S Pearle; B L McClennan; Claus G Roehrborn; Ralph V Clayman
Bolus injection v drip infusion contrast administration for ureteral stone targeting during shockwave lithotripsy.
Journal of endourology / Endourological Society 1997;11(3):163-6.
1997: Margaret S Pearle; Claus G Roehrborn
Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with sterile urine before treatment: a meta-analysis and cost-effectiveness analysis.
Urology 1997;49(5):679-86.
1997: Claus G Roehrborn; CJ Girman; T Rhodes; K A Hanson; G N Collins; SM Sech; S J Jacobsen; W M Garraway; M M Lieber
Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound.
Urology 1997;49(4):548-57.
1996: Claus G Roehrborn; A Gregory; John D McConnell; Arthur I Sagalowsky; Frank H Wians
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Urology 1996;48(6A Suppl):23-32.
1996: Claus G Roehrborn; R L Siegel
Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Urology 1996;48(3):406-15.
1996: Peter Boyle; Lawrence Gould; Claus G Roehrborn
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.
Urology 1996;48(3):398-405.
1996: Claus G Roehrborn; G J Pickens; J S Sanders
Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels.
Urology 1996;47(3):347-52.
1996: Alan L Hillman; J Sanford Schwartz; M K Willian; E Peskin; Claus G Roehrborn; J E Oesterling; M F Mason; C J Maurath; Patricia A Deverka; R J Padley
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
Urology 1996;47(2):169-78.
1996: Claus G Roehrborn; J E Oesterling; S Auerbach; S A Kaplan; L K Lloyd; D E Milam; R J Padley
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Urology 1996;47(2):159-68.
1996: Claus G Roehrborn; G J Pickens; T Carmody
Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population.
Urology 1996;47(1):59-66.
1995: Bob Djavan; S E Litwiller; Sara Milchgrub; Claus G Roehrborn
Mucinous adenocarcinoma in defunctionalized bladders.
Urology 1995;46(1):107-10.
1995: S E Litwiller; Bob Djavan; B V Klopukh; J C Richier; Claus G Roehrborn
Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders.
Urology 1995;45(5):813-22.
1995: Bob Djavan; JH Keffer; Kyle H Molberg; Claus G Roehrborn
False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney.
Urology 1995;45(5):875-8.
1994: Bob Djavan; Claus G Roehrborn
Bladder ultrasonography.
Seminars in urology 1994;12(4):306-19.
1994: Claus G Roehrborn; John D McConnell
Analysis of factors contributing to success or failure of 1-stage urethroplasty for urethral stricture disease.
The Journal of urology 1994;151(4):869-74.
1994: Claus G Roehrborn
The assessment of patient complaints.
Progress in clinical and biological research 1994;386():73-96.
1994: Claus G Roehrborn
Some socio-economic issues surrounding prostatectomy: the US experience.
Progress in clinical and biological research 1994;386():419-25.
1994: Claus G Roehrborn
The assessment of medical treatment for benign prostatic hyperplasia (BPH).
Progress in clinical and biological research 1994;386():175-90.
1993: T D Allen; Claus G Roehrborn
Pedicled preputial patch in repair of minor penile chordee with or without hypospadias.
Urology 1993;42(1):63-5.
1993: Claus G Roehrborn
Objective and subjective response criteria to diagnose benign prostatic hyperplasia.
European urology 1993;24 Suppl 1():2-11.
1992: T B Boone; Claus G Roehrborn; G Hurt
Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial.
The Journal of urology 1992;148(2 Pt 2):550-4.
1991: Claus G Roehrborn; Arthur I Sagalowsky; P C Peters
Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder.
The Journal of urology 1991;146(1):36-9.
1991: E M Reisman; T J Kennedy; Claus G Roehrborn; John D McConnell
A prospective study of urologist-performed sonographic evaluation of the urinary tract in patients with prostatism.
The Journal of urology 1991;145(6):1186-9; discussion 1189-91.
1990: Claus G Roehrborn; J T Worrell; Elizabeth Louise Wiley
Bilateral synchronous testis tumors of different histology in a patient with the acquired immunodeficiency syndrome related complex.
The Journal of urology 1990;144(2 Pt 1):353-5.
1989: Glenn M Preminger; Claus G Roehrborn
Special applications of flexible deflectable ureterorenoscopy.
Seminars in urology 1989;7(1):16-24.
1986: Claus G Roehrborn; H K Chinn; P F Fulgham; K L Simpkins; P C Peters
The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy.
The Journal of urology 1986;135(6):1190-3.